Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
GNPX Genprex Inc
- Stocks
- Healthcare
- NASDAQ: GNPX
Price (delayed)
$0.2472
Market cap
$6.88M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$2.93
Enterprise value
$3.41M
Genprex, Inc. is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Genprex's technologies are designed to administer disease-fighting genes to provide new
Highlights
The company's EPS has surged by 85% YoY and by 45% QoQ
The net income has grown by 31% year-on-year and by 9% since the previous quarter
GNPX's quick ratio has soared by 153% since the previous quarter but it is down by 25% year-on-year
Genprex's equity has soared by 139% from the previous quarter but it has plunged by 56% YoY
Key stats
What are the main financial stats of GNPX
Market
Valuations
Earnings
Shares outstanding
27.82M
Market cap
$6.88M
Enterprise value
$3.41M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.54
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$19.15M
Net income
-$19.11M
EBIT
-$19.11M
EBITDA
-$19.1M
Free cash flow
-$16.01M
Per share
Balance sheet
Liquidity
EPS
-$2.93
EPS diluted
-$2.93
Free cash flow per share
-$1.05
Book value per share
$0.45
Revenue per share
$0
TBVPS
$0.39
Total assets
$6.01M
Total liabilities
$2.14M
Debt
$0
Equity
$3.87M
Working capital
$2.02M
Debt to equity
0
Current ratio
1.94
Quick ratio
1.62
Net debt/EBITDA
0.18
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-375.5%
Return on equity
-674.3%
Return on invested capital
-3,080.2%
Return on capital employed
-494%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
GNPX stock price
How has the Genprex stock price performed over time
Intraday
4.39%
1 week
-13.35%
1 month
-3.25%
1 year
-89.79%
YTD
-70.97%
QTD
0.77%
Financial performance
How have Genprex's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$19.15M
Net income
-$19.11M
Gross margin
N/A
Net margin
N/A
The company's operating income rose by 31% YoY and by 10% QoQ
The net income has grown by 31% year-on-year and by 9% since the previous quarter
Price vs fundamentals
How does GNPX's price correlate with its fundamentals
Growth
What is Genprex's growth rate over time
Valuation
What is Genprex stock price valuation
P/E
N/A
P/B
0.54
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The company's EPS has surged by 85% YoY and by 45% QoQ
Genprex's equity has soared by 139% from the previous quarter but it has plunged by 56% YoY
The P/B is 80% below the 5-year quarterly average of 2.7 and 66% below the last 4 quarters average of 1.6
Efficiency
How efficient is Genprex business performance
The ROE has shrunk by 145% YoY and by 29% QoQ
GNPX's ROA has plunged by 88% YoY and by 19% from the previous quarter
The company's return on invested capital has surged by 77% YoY and by 33% QoQ
Dividends
What is GNPX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for GNPX.
Financial health
How did Genprex financials performed over time
Genprex's total assets is 181% higher than its total liabilities
GNPX's quick ratio has soared by 153% since the previous quarter but it is down by 25% year-on-year
GNPX's current ratio has surged by 134% since the previous quarter but it is down by 20% year-on-year
Genprex's debt is 100% lower than its equity
Genprex's equity has soared by 139% from the previous quarter but it has plunged by 56% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.